SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Lili Boulanger

PatientLili Boulanger
Date of birth2004-08-21
IdentifiersMRN HR-ET025-SYN; SSN (made up) 000-25-7731
Document date2026-01-28
AuthorOdile Marchetti-Rowe, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Results of colonoscopy, MR enterography, and tuberculosis tests. [S]

History of Present Illness

Ms. Boulanger returns nine days after presenting with four months of right lower abdominal cramping, loose stools up to six times a day and at night, evening fevers, and loss of 6 kg. The ileocolonoscopy five days ago showed deep longitudinal ulcers over the last 15 cm of the terminal ileum and patchy ulcers in the ascending and transverse colon with normal mucosa between and a spared rectum (SES-CD 14). The biopsies show chronic active ileitis and colitis with crypt distortion and a few small non-caseating granulomas; the acid-fast stain and TB PCR are negative and the mycobacterial culture is pending. MR enterography two days ago shows 18 cm of inflamed terminal ileum without stricture, fistula, abscess, or necrotic nodes. The interferon-gamma release assay is negative and the chest X-ray normal. Stool tests for Clostridioides difficile, bacterial pathogens, and parasites are negative, and celiac serology is negative. The pregnancy test is negative. She has five or six loose stools a day with cramping and fatigue (Harvey-Bradshaw Index 11). She met Dr. Nwankwo-Delacroix this morning and chose a treatment with him. She has a concert of her choral works in late March and asked whether she could still perform. [S]

ElementDetail
EndoscopyIleocolonic ulceration, SES-CD 14; rectum spared
HistologyChronic active ileocolitis with small non-caseating granulomas; AFB and TB PCR negative; culture pending
Imaging18 cm of inflamed terminal ileum; no stricture, fistula, or abscess
Infection screenIGRA negative; chest X-ray normal; HBsAg and anti-HBc negative, anti-HBs below 10; HCV and HIV negative; measles and varicella IgG positive
ActivityHarvey-Bradshaw Index 11 (moderate)

Review of Systems

SystemResultFinding
ConstitutionalPositiveFatigue and evening fevers to 37.6 °C; weight steady this week
GastrointestinalPositiveFive or six loose stools a day, one at night; right lower quadrant cramps; no blood
EyesNegativeNo red or painful eyes
MusculoskeletalNegativeNo joint pain or swelling
IntegumentaryNegativeNo tender red nodules on the shins
PsychiatricPositiveLow and anxious about the concert; PHQ-9 8, GAD-7 9

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Acetaminophen 500 mg oral tablet, one or two tablets by mouth up to every 6 hours as needed for abdominal pain, no more than 3000 mg a day; no nonsteroidal anti-inflammatory drugsOne or two tablets up to every 6 hours as neededOral route2025-12-15activeS
Prednisone 20 mg oral tablet: 40 mg by mouth each morning, reduced by 5 mg each week over eight weeks, as a bridge until risankizumab takes effect40 mg each morning, tapering by 5 mg weeklyOral route2026-01-28 to 2026-03-24completedS
Cholecalciferol (vitamin D3) 2000 units oral tablet, one tablet by mouth once dailyOne tablet once dailyOral route2026-01-28activeS
Calcium carbonate 1250 mg (500 mg elemental calcium) oral tablet, one tablet by mouth once daily with food while on prednisoneOne tablet daily with foodOral route2026-01-28 to 2026-03-24completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-01-28Body height160cmS
2026-01-28Body weight44.8kgS
2026-01-28Body mass index (BMI) [Ratio]17.5kg/m2S
2026-01-28Systolic blood pressure102mm[Hg]S
2026-01-28Diastolic blood pressure64mm[Hg]S
2026-01-28Heart rate92/minS
2026-01-28Respiratory rate16/minS
2026-01-28Body temperature37.4CelS
2026-01-28Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-01-28Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]8{score}S
2026-01-28Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]9{score}S
2026-01-28Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma18U/L<=33 U/LNormalS
2026-01-28Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma20U/L<=32 U/LNormalS
2026-01-28Bilirubin.total [Mass/volume] in Serum or Plasma0.4mg/dL<=1.2 mg/dLNormalS
2026-01-28DXA Lumbar spine [Z-score] Bone density-1.4{Z-score}A Z-score of -2.0 or below is below the expected range for ageNormalS
2026-01-28DXA Femur [Z-score] Bone density-1.1{Z-score}A Z-score of -2.0 or below is below the expected range for ageNormalS

Physical Exam

Vital signs recorded on 2026-01-28; see the Vital Signs section. [S]

SystemFinding
GeneralThin and tired; BMI 17.5
MouthTwo small aphthous ulcers inside the lower lip
AbdomenTender in the right lower quadrant with fullness but no discrete mass; no guarding
PerianalNo fistula, abscess, or skin tags
SkinNo erythema nodosum

Problems

ProblemClinical statusVerificationCodeProvenance
Crohn disease of the terminal ileum and colon (ileocolitis), Montreal A2 L3 B1 without perianal disease, moderate to severe: deep ileal ulcers over 15 cm and patchy colonic ulcers, SES-CD 14, Harvey-Bradshaw Index 11; intestinal tuberculosis excluded by negative interferon-gamma release assay, normal chest X-ray, and biopsies negative for acid-fast bacilli, TB PCR, and mycobacterial culture; synthetic modern diagnosis linked to her documented chronic intestinal illness, whose historical diagnosis is not settledactiveconfirmed K50.80S — Synthetic diagnosis confirmed within the modern episode; her historical illness is documented (D), but whether it was intestinal tuberculosis or Crohn disease remains a retrospective interpretation (R) and is disputed.
Four months of crampy right lower abdominal pain, loose stools up to six times a day including at night, low-grade evening fevers, and loss of 6 kg; inflammatory markers raised; colonoscopy and small-bowel imaging bookedresolvedconfirmed R19.7S — Synthetic presenting concern at the index visit, superseded by the diagnosis; the documented symptoms of early 1915 are echoed (D).
Iron deficiency anemia from chronic intestinal blood loss and poor absorption (hemoglobin 10.6 g/dL, MCV 76, ferritin 9)activeconfirmed D50.0S — Synthetic finding at presentation; corrected by intravenous iron.
Moderate protein-calorie malnutrition: BMI 17.6 after losing 6 kg (12 percent of body weight) in four months; albumin 3.3 g/dLactiveconfirmed E44.0S — Synthetic nutritional status at presentation; resolved with treatment and dietitian support.
Vitamin D deficiency (25-hydroxyvitamin D 18 ng/mL)activeconfirmed E55.9S — Synthetic finding at presentation.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ImagingIleocolonoscopy with biopsiesAt diagnosisUp to dateFive days ago: SES-CD 14; chronic active ileocolitis with small non-caseating granulomas
ImagingCross-sectional imaging of the small bowel (MR enterography)At diagnosis, for extent and complicationsUp to dateTwo days ago: 18 cm of inflamed terminal ileum; no stricture, fistula, or abscess
LaboratoryExclusion of intestinal tuberculosis: biopsy acid-fast stain, TB PCR, and mycobacterial cultureAt diagnosis, before immunosuppressionUp to dateAcid-fast stain and TB PCR negative; culture pending, to be reviewed at six weeks
LaboratoryLatent tuberculosis screen (interferon-gamma release assay) and chest X-rayBefore steroids or a biologicUp to dateIGRA negative; chest X-ray normal
LaboratoryHepatitis B, hepatitis C, and HIV screeningBefore immunosuppressionUp to dateHBsAg and anti-HBc negative; anti-HBs below 10 mIU/mL after an infant series; HCV antibody and HIV negative
LaboratoryStool tests for Clostridioides difficile and enteric pathogens; celiac serologyAt diagnosisUp to dateAll negative
LaboratoryLiver enzymes and bilirubin before risankizumabAt baselineCompleted todayALT 18, AST 20, bilirubin 0.4
Medication safetyVaccines before immunosuppressionBefore starting, when possibleCompleted todayPCV20, recombinant zoster dose 1, and a hepatitis B booster today; immune to measles and varicella, so no live vaccine is needed and treatment need not wait
LaboratoryHepatitis B antibody after the boosterOne to two months after the doseDueAt the next visit
ImagingBone density (DXA)At diagnosis with risk factors (low weight, vitamin D deficiency, corticosteroids)Completed todayLumbar spine Z-score -1.4, femoral neck -1.1: within the expected range for age
SurveyDepression and anxiety screen (PHQ-9 and GAD-7)At diagnosis and at least yearlyCompleted todayPHQ-9 8 and GAD-7 9, mild; offered the IBD psychology service
ReferralGastroenterology (inflammatory bowel disease)At diagnosisCompleted todaySeen this morning; recommendations in the consultation note
Self-managementDietitian and nutrition planAt diagnosis with weight lossCompleted todaySeen today; supplements started
Self-managementContraception and pregnancy planningAt diagnosis for women of reproductive ageCompleted todayNot sexually active; pregnancy test negative; counseled to avoid pregnancy while the disease is active and to plan any pregnancy in remission
Self-managementSmoking statusEvery visitCompleted todayNever smoker

Goal progress:

Immunizations given today: Pneumococcal conjugate vaccine PCV20, before immunosuppression; Recombinant zoster vaccine, dose 1 of 2, before immunosuppression; Hepatitis B vaccine, adult booster dose (infant series, anti-HBs below 10 mIU/mL) [S]

Guideline basis: ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol 2025;120(6):1225-1264 (2025); AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. Gastroenterology 2021 (2021); ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. J Crohns Colitis 2024;18(10):1531-1555 (2024); ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. J Crohns Colitis 2026 (2026); ACG Clinical Guideline Update: Preventive Care in Inflammatory Bowel Disease. Am J Gastroenterol 2025;120:1447-1473 (2025); SKYRIZI (risankizumab-rzaa): prescribing information (Crohn disease dosing; hepatotoxicity monitoring; tuberculosis evaluation; immunizations) (2026)

Follow-up: First risankizumab infusion and intravenous iron in five days. Review at the second infusion, in four weeks. Next scheduled visit 2026-03-02: review at week 4 of risankizumab, on the day of the second induction infusion. [S]